OncoCyte’s (OCX) Equal Weight Rating Reiterated at Stephens

OncoCyte (NASDAQ:OCX)‘s stock had its “equal weight” rating reiterated by Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $4.00 target price on the stock. Stephens’ target price indicates a potential upside of 29.03% from the stock’s current price.

Other equities analysts have also issued reports about the company. StockNews.com began coverage on OncoCyte in a report on Monday, January 13th. They issued a “sell” rating for the company. Needham & Company LLC reissued a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research note on Tuesday.

OncoCyte Stock Down 6.9 %

Shares of OncoCyte stock traded down $0.23 during trading on Tuesday, hitting $3.10. 42,017 shares of the stock were exchanged, compared to its average volume of 65,653. The stock’s fifty day moving average is $2.71 and its 200 day moving average is $2.72. OncoCyte has a 12 month low of $1.92 and a 12 month high of $4.75.

Insiders Place Their Bets

In other OncoCyte news, major shareholder Patrick W. Smith bought 90,219 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was acquired at an average price of $2.13 per share, with a total value of $192,166.47. Following the completion of the transaction, the insider now directly owns 1,773,903 shares in the company, valued at approximately $3,778,413.39. This represents a 5.36 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrea S. James bought 97,561 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was acquired at an average price of $2.05 per share, for a total transaction of $200,000.05. Following the acquisition, the chief financial officer now directly owns 151,231 shares in the company, valued at $310,023.55. This trade represents a 181.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 1,288,344 shares of company stock worth $2,649,051 over the last ninety days. Company insiders own 1.58% of the company’s stock.

Institutional Investors Weigh In On OncoCyte

A number of institutional investors have recently modified their holdings of OCX. FNY Investment Advisers LLC grew its holdings in OncoCyte by 15.1% during the fourth quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company’s stock valued at $117,000 after purchasing an additional 6,481 shares during the last quarter. Ground Swell Capital LLC acquired a new stake in OncoCyte during the fourth quarter worth $26,000. Geode Capital Management LLC boosted its holdings in OncoCyte by 12.2% during the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company’s stock valued at $296,000 after purchasing an additional 11,289 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in shares of OncoCyte in the 4th quarter valued at $31,000. Finally, Wealthedge Investment Advisors LLC acquired a new position in OncoCyte in the fourth quarter valued at about $126,000. Institutional investors and hedge funds own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.